Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 20, 2022 12:00 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference

HOUSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing medicines for patients fighting cancer and in need of...
September 13, 2022 08:00 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals CEO Issues Letter to Stockholders

HOUSTON, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing medicines for patients fighting cancer and in need of...
August 22, 2022 08:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Adds Two Mayo Clinic Sites to its Ongoing Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing’s Sarcoma and FET-Rearranged Sarcomas

Expands Trial to 17 U.S. Sites and 25 Locations Initiation of All Anticipated U.S. Trial Sites Largely Completed HOUSTON, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:...
August 08, 2022 08:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment...
August 04, 2022 08:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

HOUSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new...
August 02, 2022 08:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement

HOUSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new...
July 29, 2022 09:15 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals to Host Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 8, 2022

HOUSTON, July 29, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment...
June 09, 2022 07:33 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals to Participate in BIO International Convention 2022

HOUSTON, Texas, June 09, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new...
May 18, 2022 16:10 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

HOUSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
May 12, 2022 16:05 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results

Salarius Successfully Completes SP-3164 Pre-IND Meeting Process with FDA Advancing multiple drug development programs, led by SP-3164 in targeted protein degradation, and seclidemstat in protein...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right